APIE Therapeutics Appoints Ashwin Datt Chief Executive Officer
Former CEO and Founder, Esther Alegria, Remains on Executive Team Focused on Driving Research & Development Through External Collaborations
APIE Therapeutics Welcomes Jim Greenwood to its Board of Directors
Cary, NC — APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced the appointment of Jim Greenwood, former president & CEO of the Biotechnology Innovation Organization (BIO), to its board of directors. “Jim is known in the industry for his long tenure as president and CEO […]
APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
Presentation at IPF Summit Elucidates APT-101 Mechanism of Action
International Workshop of Scleroderma Research
Preclinical results support the potential of APT-101 as a therapeutic for ILD, including those cases associated with SSc-ILD
APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis
APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research
